Treatment of Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

Inclusion criteria

• Clinical diagnosis of patients with pseudovitellium detachment.
• Patients must be at least 18 years of age.
• Visual acuity of 20/30 to 20/320 in study eye on the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart
• Visual acuity of 20/800 or better in fellow eye on the ETDRS visual acuity chart

Exclusion criteria

• Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.
• Patients who have undergone intraocular surgery within the last 2 months.
• Patient participating in any other investigational drug study.
• Use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication.
• Inability to obtain photographs to document choroidal neovascularization (CNV) (including difficulty with venous access).
• Patient with significant liver disease or uremia.
• Patient with known adverse reaction to fluorescein and indocyanine green or iodine.
• Patient has a history of any medical condition which would preclude scheduled visits or completion of study
• Patient has had insertion of scleral buckle in the study eye
• Patient has received radiation treatment
• Patient is on anticoagulant therapy with the exception of aspirin
• Patient is pregnant or nursing.